John Wiley and Sons Ltd, April 2008, Pages: 160
that assists them in identifying those MCI patients who will progress to recognised Alzheimer’s Disease.
Beautifully presented in full colour, Early Diagnosis and Treatment of MildCognitiveImpairment
GlobalData, Jan 2011, Pages: 69
MildCognitiveImpairment Global Clinical Trials Review, Q1, 2011
Summary
Our clinical trial report, “MildCognitiveImpairment Global Clinical Trials Review, Q1, 2011" provides data on the Mild
Global Markets Direct, Dec 2010, Pages: 27
MildCognitiveImpairment - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “MildCognitiveImpairment Pipeline Review, Q4 2010”, provides an overview of the MildCognitiveImpairment
Global Markets Direct, Aug 2011, Pages: 135
MildCognitiveImpairment - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'MildCognitiveImpairment - Pipeline Review, H2 2011', provides an overview of the MildCognitiveImpairment
Global Markets Direct, April 2011, Pages: 167
MildCognitiveImpairment - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'MildCognitiveImpairment - Pipeline Review, Q2 2011', provides an overview of the MildCognitiveImpairment
Clinical Publishing, March 2007, Pages: 208
This thoughtful new work begins by asking the question ‘what is normal in cognitive and pathological ageing?’ The clinician’s experience of dementia and mildcognitiveimpairment suggests
Apollo Managed Care Consultants, May 2011, Pages: 66
References list for the introduction
Evidence-based Medicine web sites
Behavioral Health Care – Access to care
Introduction and differential diagnosis
MildCognitiveImpairment (MCI)
Contributing factors
Informa Healthcare, Nov 2010, Pages: 264
of Dementia. Diagnosis of MildCognitiveImpairment and Dementia Maria. Pharmacotherapy of Cognition. Management of Behaviors. Management of Function - Instrumental Activities of Daily Living. Management
Datamonitor, Nov 2011, Pages: 55
, solanezumab, and Gammagard have the potential to grow the market by $7.6bn. Datamonitor forecasts that around 600,000 patients with mildcognitiveimpairment or mild to moderate Alzheimer’s disease will receive
Jain PharmaBiotech, Feb 2012, Pages: 534
phase
Differentiation of AD from other dementias
Differentiation of AD from non-dementing disorders
Cerebral insufficiency and AD
Memory deficits and preclinical AD
Mildcognitiveimpairment
Elsevier Science and Technology, July 2009, Pages: 360
Fernandez, Brian Giunta, Mike R. Schoenberg, Jun Tan
3. Proton magnetic resonance spectroscopy in dementias and mildcognitiveimpairment
H. Randall Griffith, Christopher C. Stewart, Jan A. den Hollander
4
Business Insights, May 2011, Pages: 273
agonists as cognition enhancers and disease modifiers
About the author
Disclaimer
Introduction
Summary
Introduction
Diagnosis of Alzheimer’s disease and mildcognitiveimpairment
Prevalence
Medpredict, May 2010, Pages: 143
a heart attack in a patient with high blood pressure and high cholesterol, the neurologist or gerontologist must be able to identify people who are at risk of developing mildcognitiveimpairment
Datamonitor, Nov 2011, Pages: 150
- Datamonitor???s physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mildcognitiveimpairment to severe Alzheimer’s disease. However, Eisai faces a steep
VDM Publishing House, Dec 2009, Pages: 136
. Furthermore, diabetic animals present hippocampal pathology suggesting mild neurodegeneration. Concurrently, cognitiveimpairments related to spatial memory were found. Finally, normalization of the hippocampal
GlobalData, Nov 2010, Pages: 43
And Subsidiaries
Head Office
Recent Developments
Oct 06, 2010: Adeona Completes 100% Enrollment In Pivotal Alzheimer’s Disease And MildCognitiveImpairment Clinical Study
Oct 06, 2010: Adeona Completes 100
Datamonitor, Dec 2010, Pages: 35
CognitiveImpairment
Race and Ethnicity
CO-MORBIDITIES
Seizures may be a co-morbidity or indicative of early onset of the disease
EPIDEMIOLOGIC FORECASTING OF ALZHEIMER’S DISEASE
Sources of epidemiologic
Global Markets Direct, March 2011, Pages: 39
% Enrollment In Pivotal Alzheimer’s Disease And MildCognitiveImpairment Clinical Study
Oct 06, 2010: Adeona Completes 100% Enrollment In Pivotal Alzheimer’s Disease And MildCognitiveImpairment Clinical
